Highly Pathogenic Avian Influenza (HPAI) H5N1 Virus in Livestock
The primary introduction of disease into dairy herds has been predominantly via exposure to wild birds. The exact mechanism of spread is currently unknown, although there is potential for viral spread through milk.
Cluster of Influenza A(H5) Cases Associated with Poultry Exposure at Two Facilities — Colorado
Persons who work in close contact with dairy cattle and poultry that are infected with highly pathogenic avian influenza (HPAI) A(H5N1) virus are at increased risk for infection.
Three new studies probe the efficacy of antivirals in preventing and treating influenza
Two find that the drugs may shorten hospital stays and decrease the risk of infection in those at high risk for severe illness, and one concludes that timely initiation reduces the risk of death from flu-related pneumonia.
Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study
By March, 2023, 54 countries, areas, and territories (hereafter CAT) in the WHO European Region had reported more than 2·2 million COVID-19-related deaths to the WHO Regional Office for Europe.
Infection of South American coatis (Nasua nasua) with highly pathogenic avian influenza H5N1 virus displaying mammalian adaptive mutations
Deadly outbreaks among poultry, wild birds, and carnivorous mammals by the highly pathogenic H5N1 virus of the clade 2.3.4.4b have been reported in South America.
Opportunities and challenges for the U.S. laboratory response to highly pathogenic avian influenza A(H5N1)
On March 25, 2024 an outbreak of highly pathogenic avian influenza (HPAI) A H5N1 was identified in dairy cows across multiple farms in the United States.
France to launch 2nd vaccination campaign against AI H5N1
In a significant move to protect its poultry industry, France is set to launch its second commercial vaccination campaign against Avian Influenza H5N1.
Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials
The optimal antiviral drug for treatment of severe influenza remains unclear. To support updated WHO influenza clinical guidelines, this systematic review and network meta-analysis evaluated antivirals for treatment of patients with severe influenza.
Article
Scientific Papers
News
Uncovering the Contrasts and Connections in PASC: Viral Load and Cytokine Signatures in Acute COVID-19 versus Post-Acute Sequelae of SARS-CoV-2 (PASC)
The recent global COVID-19 pandemic has had a profound and enduring impact, resulting in substantial loss of life.
What do B- and T-cells do and how do they respond?
ESWI addresses common questions and misconceptions amongst the general public regarding influenza, COVID-19 and RSV. These responses, elaborated by ESWI Board Members and coalition partners, aim to increase public awareness and prevent misinformation.
When should you take antiviral drugs?
ESWI addresses common questions and misconceptions amongst the general public regarding influenza, COVID-19 and RSV. These responses, elaborated by ESWI Board Members and coalition partners, aim to increase public awareness and prevent misinformation.
What is the difference between monovalent and polyvalent vaccines?
ESWI addresses common questions and misconceptions amongst the general public regarding influenza, COVID-19 and RSV. These responses, elaborated by ESWI Board Members and coalition partners, aim to increase public awareness and prevent misinformation.
